These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

490 related items for PubMed ID: 25542295

  • 1. Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis.
    Zivadinov R, Dwyer M, Barkay H, Steinerman JR, Knappertz V, Khan O.
    J Neurol; 2015 Mar; 262(3):648-53. PubMed ID: 25542295
    [Abstract] [Full Text] [Related]

  • 2. The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis.
    Zivadinov R, Dwyer MG, Ramasamy DP, Davis MD, Steinerman JR, Khan O.
    J Neuroimaging; 2015 Mar; 25(6):989-95. PubMed ID: 26394270
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center.
    Wolinsky JS, Narayana PA, Johnson KP, Multiple Sclerosis Study Group and the MRI Analysis Center.
    Mult Scler; 2001 Feb; 7(1):33-41. PubMed ID: 11321192
    [Abstract] [Full Text] [Related]

  • 7. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
    Cohen J, Belova A, Selmaj K, Wolf C, Sormani MP, Oberyé J, van den Tweel E, Mulder R, Koper N, Voortman G, Barkhof F, Glatiramer Acetate Clinical Trial to Assess Equivalence With Copaxone (GATE) Study Group.
    JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034
    [Abstract] [Full Text] [Related]

  • 8. Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS.
    Arnold DL, Campagnolo D, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, Vollmer T.
    J Neurol; 2008 Oct; 255(10):1473-8. PubMed ID: 18854910
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.
    Radue EW, O'Connor P, Polman CH, Hohlfeld R, Calabresi P, Selmaj K, Mueller-Lenke N, Agoropoulou C, Holdbrook F, de Vera A, Zhang-Auberson L, Francis G, Burtin P, Kappos L, FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group.
    Arch Neurol; 2012 Oct; 69(10):1259-69. PubMed ID: 22751847
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
    Comi G, Filippi M, Wolinsky JS.
    Ann Neurol; 2001 Mar; 49(3):290-7. PubMed ID: 11261502
    [Abstract] [Full Text] [Related]

  • 14. An MRI-defined measure of cerebral lesion severity to assess therapeutic effects in multiple sclerosis.
    Kim G, Tauhid S, Dupuy SL, Tummala S, Khalid F, Healy BC, Bakshi R.
    J Neurol; 2016 Mar; 263(3):531-8. PubMed ID: 26754005
    [Abstract] [Full Text] [Related]

  • 15. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
    Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT, CONFIRM Study Investigators.
    N Engl J Med; 2012 Sep 20; 367(12):1087-97. PubMed ID: 22992072
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Magnetization transfer imaging of acute black holes in patients on glatiramer acetate.
    Zivadinov R, Hussein S, Bergsland N, Minagar A, Dwyer MG.
    Front Biosci (Elite Ed); 2012 Jan 01; 4(4):1496-504. PubMed ID: 22201970
    [Abstract] [Full Text] [Related]

  • 18. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.
    Filippi M, Rocca MA, Pagani E, De Stefano N, Jeffery D, Kappos L, Montalban X, Boyko AN, Comi G, ALLEGRO Study Group.
    J Neurol Neurosurg Psychiatry; 2014 Aug 01; 85(8):851-8. PubMed ID: 24029546
    [Abstract] [Full Text] [Related]

  • 19. MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b.
    Brown RA, Narayanan S, Stikov N, Cook S, Cadavid D, Wolansky L, Arnold DL.
    Neurology; 2016 Aug 30; 87(9):905-11. PubMed ID: 27473139
    [Abstract] [Full Text] [Related]

  • 20. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study.
    Gold R, Arnold DL, Bar-Or A, Hutchinson M, Kappos L, Havrdova E, MacManus DG, Yousry TA, Pozzilli C, Selmaj K, Sweetser MT, Zhang R, Yang M, Potts J, Novas M, Miller DH, Kurukulasuriya NC, Fox RJ, Phillips TJ.
    Mult Scler; 2017 Feb 30; 23(2):253-265. PubMed ID: 27207449
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.